Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14167755 | 0.83 | CYP11B2 (0.41) | CA1CA2PDE3BPDE3A | |
| SCHEMBL30899561 | 0.80 | CA1 (0.34) | CA1CA2 | |
| SCHEMBL22714416 | 0.80 | CA1 (0.34) | CA1CA2 | |
| SCHEMBL32675744 | 0.73 | ABL1 (0.34) | CA1CA2KMT2ACRBN | |
| SCHEMBL15464796 | 0.72 | CYP11B2 (0.41) | CA1CA2 | |
| SCHEMBL22714393 | 0.72 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL30899562 | 0.72 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL22714352 | 0.71 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL30899575 | 0.71 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL16965654 | 0.70 | CA1 (0.43) | CA1CA2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012168315-A1 | SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |